The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes with 177 lutetium-dotatate (177Lu-dotatate) in olfactory neuroblastoma (ONB): A case series.
 
Mateus Trinconi Cunha
No Relationships to Disclose
 
Lesley Flynt
No Relationships to Disclose
 
Matheus Sewastjanow-Silva
No Relationships to Disclose
 
Kaiwen Wang
Consulting or Advisory Role - BluPrint Oncology
 
Jack Phan
No Relationships to Disclose
 
Melissa Chen
No Relationships to Disclose
 
Luana Sousa
Consulting or Advisory Role - Coherus BioSciences
Research Funding - Agenus (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Dava Oncology
 
Neal Akhave
Honoraria - American Society of Clinical Oncology
Consulting or Advisory Role - Genmab/Seagen
Research Funding - AVEO (Inst); Bicara Therapeutics (Inst); Innocare (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - American Society of Clinical Oncology; Genmab/Seagen
 
Michelle Williams
Speakers' Bureau - Springer
Research Funding - Bayer Health
 
Ehab Hanna
No Relationships to Disclose
 
Shirley Su
Stock and Other Ownership Interests - CSL Limited; Intellia Therapeutics; ResMed
Travel, Accommodations, Expenses - Medtronic
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Bicara Therapeutics; Coherus Biosciences; Eisai; Labcorp Drug Development; Raptor Pharmaceuticals; Regeneron; Rgenta
Research Funding - Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Remix Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year
Travel, Accommodations, Expenses - Bicara Therapeutics